Repligen shares have delivered mixed results for long term holders, with the stock down 34.9% over five years even as cash flow expectations keep evolving. That leaves a clear question for anyone looking at Repligen today: is the current price adequately supported by the cash the business is expected to generate?
- The 34.9% decline over the past five years has reshaped the experience for longer term shareholders and puts the focus squarely on what the company’s future cash flows are worth.
- The completed acquisition of BioLife Solutions brings in a consumables focused cell therapy portfolio that may support higher recurring revenue and could influence the stability and timing of Repligen’s future cash generation.
- What if you looked at Repligen through its sales instead? See why Repligen's 12.5x P/S tells a different valuation story.
For investors, the debate is whether Repligen’s current share price can be justified by its cash flows when valued using a Discounted Cash Flow (DCF) view of intrinsic value.
If you want to stress test whether Repligen's cash flow debate applies elsewhere, compare it to other 29 high quality undervalued stocks.
Does Repligen Look Fairly Valued on Cash Flow?
The Discounted Cash Flow (DCF) approach here values Repligen on the cash it is expected to generate for shareholders. The model starts from last twelve month free cash flow of about $100.9 million and then assumes that cash generation grows from this base rather than shrinking. Growth expectations are front loaded into the next several years, then taper into a slower phase as the business matures.
Those rising projections leave Repligen’s estimated intrinsic value broadly in line with the current share price of $173.88. Because the acquisition of BioLife Solutions adds a consumables heavy cell therapy portfolio, the market already appears to be treating that extra recurring cash potential as largely reflected in today’s quote. Find out what Repligen could be worth using our Discounted Cash Flow (DCF) estimate.
The Repligen Narrative: What Would Justify Today's Price?
Repligen’s valuation puzzle only really comes into focus once you spell out the stories that could sit behind the cash flow math. Simply Wall St Narratives pick up here by laying out clear, competing views on Repligen’s future growth, margins and earnings that would need to hold for the stock to be worth meaningfully more or less than today’s price. Each one treats fair value as a thesis about the business that you can track over time rather than a single static number.
Community views on Repligen are split between those who see more upside left in the story and those who think recent optimism has gone far enough.
Bull case: 11% undervalued
"Bullish analysts describe Repligen as a differentiated pure-play bioprocessing company and note that its exposure to clinical-stage programs and ongoing product development could support mid-teens revenue growth and 30% margins..."
Discover why this Narrative puts Repligen at 11% undervalued.
Bear case: 16% overvalued
"Bearish analysts point to the acquisition of BioLife at $31 per share as a potential source of integration and execution risk, which could weigh on Repligen's growth profile if synergies or product fit are slower to materialize..."
Explore why this Narrative puts Repligen at 16% overvalued.
One more angle on Repligen that deserves your attention
Before you weigh Repligen purely on its cash flow profile, it is worth looking at the specific concerns our broader checks have highlighted and deciding how much those issues matter to you. Take a closer look at 1 warning sign before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com